M. Mazier

693 total citations
10 papers, 551 citations indexed

About

M. Mazier is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, M. Mazier has authored 10 papers receiving a total of 551 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in M. Mazier's work include Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (6 papers) and Gastric Cancer Management and Outcomes (5 papers). M. Mazier is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (6 papers) and Gastric Cancer Management and Outcomes (5 papers). M. Mazier collaborates with scholars based in Australia, Spain and Greece. M. Mazier's co-authors include Fernando Rivera, David Cunningham, Maria Di Bartolomeo, Scott Berry, Albrecht Kretzschmar, M. Michael, Eric Van Cutsem, John Bridgewater, Marc Peeters and J.-L. Canon and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

M. Mazier

10 papers receiving 535 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Mazier Australia 7 495 214 202 84 61 10 551
Anna Świeboda-Sadlej Poland 8 248 0.5× 153 0.7× 101 0.5× 145 1.7× 29 0.5× 16 385
Tae Won Kim South Korea 8 616 1.2× 258 1.2× 169 0.8× 86 1.0× 110 1.8× 17 699
Fritz Lang Austria 12 534 1.1× 240 1.1× 88 0.4× 54 0.6× 187 3.1× 16 640
M. Kozloff United States 12 273 0.6× 138 0.6× 64 0.3× 54 0.6× 26 0.4× 29 352
Ernesto Durini Italy 7 629 1.3× 277 1.3× 222 1.1× 88 1.0× 117 1.9× 14 732
Elisabetta Alafaci Italy 4 473 1.0× 152 0.7× 299 1.5× 40 0.5× 185 3.0× 7 580
Silvija Kraljevic United States 8 178 0.4× 142 0.7× 157 0.8× 67 0.8× 24 0.4× 15 327
J McKendrick Australia 9 338 0.7× 180 0.8× 38 0.2× 121 1.4× 81 1.3× 24 525
Miah Hiang Tay Singapore 11 157 0.3× 207 1.0× 73 0.4× 112 1.3× 59 1.0× 23 437
Seonggyu Byeon South Korea 11 283 0.6× 195 0.9× 68 0.3× 79 0.9× 39 0.6× 30 442

Countries citing papers authored by M. Mazier

Since Specialization
Citations

This map shows the geographic impact of M. Mazier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Mazier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Mazier more than expected).

Fields of papers citing papers by M. Mazier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Mazier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Mazier. The network helps show where M. Mazier may publish in the future.

Co-authorship network of co-authors of M. Mazier

This figure shows the co-authorship network connecting the top 25 collaborators of M. Mazier. A scholar is included among the top collaborators of M. Mazier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Mazier. M. Mazier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
2.
Dimopoulos, Meletios Α., Meral Beksaç, Lotfi Benboubker, et al.. (2011). Bortezomib-Dexamethasone Alone or Plus Cyclophosphamide or Lenalidomide As Second-Line Treatment for Patients with Multiple Myeloma: Final Results From a Phase 2 Study. Blood. 118(21). 1861–1861. 1 indexed citations
3.
Cutsem, Eric Van, Fernando Rivera, Sean L. Berry, et al.. (2009). SAFETY AND EFFICACY OF BEVACIZUMAB (BEV) AND CHEMOTHERAPY IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): RESULTS FROM THE BEAT OBSERVATIONAL COHORT STUDY. UCL Discovery (University College London). 5 indexed citations
4.
Cutsem, Eric Van, Fernando Rivera, Scott Berry, et al.. (2009). Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Annals of Oncology. 20(11). 1842–1847. 423 indexed citations
5.
Cutsem, Eric Van, Francisca Rivera, Scott Berry, et al.. (2009). 6088 Safety and efficacy of bevacizumab (BEV) and chemotherapy in elderly patients with metastatic colorectal cancer (mCRC): results from the BEAT observational cohort study. European Journal of Cancer Supplements. 7(2). 349–349. 6 indexed citations
6.
Berry, Scott, Eric Van Cutsem, Albrecht Kretzschmar, et al.. (2008). Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT. Journal of Clinical Oncology. 26(15_suppl). 4025–4025. 19 indexed citations
7.
Kretzschmar, Albrecht, Eric Van Cutsem, M. Michael, et al.. (2007). Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEATrial. Journal of Clinical Oncology. 25(18_suppl). 4072–4072. 14 indexed citations
8.
Berry, Scott, David Cunningham, Albrecht Kretzschmar, et al.. (2007). 3020 POSTER Preliminary efficacy of Bevacizumab with first-line Folfox, Xelox, Folfiri and fluoropyrimidines for mCRC: First BEAT trial. European Journal of Cancer Supplements. 5(4). 241–241. 6 indexed citations
9.
Berry, Scott, David Cunningham, M. Michael, et al.. (2006). Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC—First B.E.A.Trial. Journal of Clinical Oncology. 24(18_suppl). 3534–3534. 40 indexed citations
10.
Michael, M., A. Kretzschmar, Scott Berry, et al.. (2006). Feasibility of metastasectomy in patients treated with bevacizumab in first-line mCRC - Preliminary results from the First Beat-study. Journal of Clinical Oncology. 24(18_suppl). 3523–3523. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Świeboda-Sadlej Breakdown of academic impact, for papers by Tae Won Kim Breakdown of academic impact, for papers by Fritz Lang Breakdown of academic impact, for papers by M. Kozloff Breakdown of academic impact, for papers by Ernesto Durini Breakdown of academic impact, for papers by Elisabetta Alafaci Breakdown of academic impact, for papers by Silvija Kraljevic Breakdown of academic impact, for papers by J McKendrick Breakdown of academic impact, for papers by Miah Hiang Tay Breakdown of academic impact, for papers by Seonggyu Byeon
Rankless by CCL
2026